United States Blood Collection Devices Market Overview, 2031

Key Insights

• According to the research report, "USA Blood Collection Devices Market Outlook, 2031," published by Bonafide Research, the USA Blood Collection Devices Market was valued at more than 2.85 Billion in 2025.
• The USA blood collection devices market is undergoing a major shift toward decentralized sampling. Traditional venous draws in clinical settings are increasingly being supplemented by painless capillary microsampling tools and upper-arm devices, driven by patient demand for remote healthcare, home diagnostics, and decentralized clinical trials. Additionally, widespread staffing shortages among certified phlebotomists are forcing healthcare institutions to adopt automated sampling workflows. These automated systems accelerate sample throughput by up to 20%, standardize blood collection, and significantly reduce human-error pre-analytical contamination rates in clinical laboratories.
• On the technological front, a major breakthrough transforming the space is the development and regulatory clearance of fully autonomous robotic blood-drawing platforms, such as FDA-cleared autonomous venipuncture devices. These standalone systems combine artificial intelligence with near-infrared imaging and ultrasound guidance to locate veins and perform venipunctures without direct human intervention.
• The clinical and operational baseline of the U.S. market relies on massive recurring consumable demand. Single-use consumables including needles, blood bags, lancets, and vacuum-sealed collection tubes comprise approximately 76.6% of overall revenue. This continuous demand is sustained by more than 317,000 CLIA-registered laboratories operating nationwide, alongside daily hospital usage exceeding 29,000 units of red blood cells, 5,000 units of platelets, and 6,500 units of plasma across 16 million annual transfusions.

Market Outlook

• The market is set to expand rapidly around ambient-temperature sample logistics and at-home micro-collection kits designed for direct integration into telehealth pathways. Driven by direct-to-consumer health testing and remote therapeutic drug monitoring, self-collection technologies such as volumetric absorptive microsampling (VAMS) and push-button capillary devices will become routine tools for chronic disease management and decentralized trial monitoring, bypassing the need for in-person phlebotomy visits.
• Concurrently, regulatory mandates and occupational health guidelines from agencies like OSHA will enforce stricter standardization of safety-engineered blood collection systems. Dual-shield safety needles, self-retracting lancets, and closed vacuum collection loops will remain non-negotiable standards across ambulatory care and acute healthcare centers to eliminate needle-stick injuries and accidental blood exposure hazards.
• Prominent market players spearheading these technologies include Becton, Dickinson and Company (BD), Terumo Blood and Cell Technologies, Cardinal Health, Fresenius SE & Co., Tasso Inc., and QIAGEN, which operate in coordination with key industry bodies like the AABB (Association for the Advancement of Blood & Biotherapies) and America’s Blood Centers (ABC).

Market Dynamics

Driver: Surge in chronic diseases and diagnostics demand
The continuous rise in chronic illness prevalence across the U.S. including diabetes, cardiovascular conditions, autoimmune disorders, and various cancers is the primary operational driver for blood collection devices. Managing and monitoring these conditions requires routine diagnostic panels, therapeutic monitoring, and blood testing. This constant requirement for diagnostic blood draws ensures high volume, recurring demand for fundamental single-use collection hardware such as vacuum tubes, safety needles, and blood transfer sets.
Challenge: Sample hemolysis and pre-analytical errors
Pre-analytical errors during blood collection primarily specimen hemolysis caused by difficult venous access, incorrect needle gauges, improper tube mixing, or over-aspiration remain a significant challenge for healthcare providers. Hemolyzed samples contaminate diagnostic reads, leading to specimen rejections by clinical laboratories, required redraws, increased operational costs, and patient distress. Designing devices that minimize sheer stress on red blood cells while maintaining ease of use for varied clinical skill levels is an ongoing technical hurdle.
Trend: Rapid adoption of upper-arm capillary microsampling
The market is rapidly adopting upper-arm capillary microsampling devices as an alternative to traditional venipunctures. These push-button, low-pain devices utilize micro-needles combined with gentle vacuum extraction to collect small volumes of whole capillary blood. This trend aligns with the expansion of decentralized clinical trials, direct-to-consumer lab testing, and home-based patient monitoring by eliminating the need for a trained phlebotomist to perform every routine draw.

Regulations and Policies

• FDA Device Classification and 510(k) Clearance: Blood collection devices (including evacuated tubes, safety needles, lancets, and microsampling systems) are regulated as Class II medical devices by the FDA. Manufacturers must obtain 510(k) premarket clearance demonstrating substantial equivalence to a legally marketed predicate device before commercial distribution.
• OSHA Bloodborne Pathogens Standard (29 CFR 1910.1030): Enforced by the Occupational Safety and Health Administration (OSHA), this regulation mandates the mandatory implementation of Engineering and Work Practice Controls. It legally dictates the use of safety-engineered sharp devices (e.g., self-retracting needles, shielded butterfly sets) to eliminate occupational needle-stick injuries and worker exposure to bloodborne pathogens.
• Needlestick Safety and Prevention Act: Enacted to bolster OSHA requirements, this federal mandate requires healthcare facilities to continuously evaluate and adopt safer medical devices equipped with built-in needle safety features and document device evaluation processes annually.
• FDA CBER Oversight for Blood Banking and Transfusions: The Center for Biologics Evaluation and Research (CBER) oversees specialized blood collection equipment, anticoagulants, and apheresis bags specifically utilized for blood donations, donor screening, and therapeutic blood component manufacturing.

Segment Analysis

USA Blood Collection Devices Market By Product Type
• Blood collection tubes remain a foundational component of U.S. specimen workflows because tube selection directly affects specimen integrity, analyte stability, and downstream laboratory compatibility. The market is increasingly differentiated by tube chemistry and application rather than by the basic container itself, with EDTA, citrate, heparin, serum-separating, and plasma-oriented formats supporting distinct testing requirements.
• Needles and syringes are evolving from basic blood-access instruments toward safety-oriented and application-specific collection components. U.S. demand is shaped by the need to reduce needlestick exposure, improve first-attempt collection, support difficult-access patients, and accommodate specialized procedures such as arterial blood sampling. Product differentiation increasingly involves safety mechanisms, needle geometry, blood-flow characteristics, connectivity, and integration with closed collection systems.
• Blood bags occupy a distinctive position because they connect collection with the subsequent processing, storage, separation, and transfusion of blood components. In the U.S., their value is closely tied to blood-supply safety, component preparation, sterility, traceability, and compatibility with blood-processing equipment. Rather than functioning solely as collection containers, modern blood-bag systems can form part of integrated workflows for separating components such as red cells, plasma, and platelets.
• Blood collection systems and monitors represent the market's shift toward greater control over collection quality and workflow visibility. These products can combine collection hardware with monitoring, pressure management, connectivity, or process-control capabilities, making them particularly relevant where reproducibility and documentation are important.
• Lancets are increasingly associated with decentralized and minimally invasive sampling rather than conventional hospital venipuncture. Their relevance extends across point-of-care testing, diabetes monitoring, screening programs, and settings where only a small blood volume is required. A particularly important U.S. market characteristic is the strong emphasis on single-patient use and sharps-safety design.
• Others category encompasses specialized products that support blood acquisition without fitting neatly into the major tube, needle, bag, monitor, or lancet groups. This can include capillary micro-collection components, specialized transfer devices, collection accessories, and application-specific sampling products. The category is becoming more relevant as U.S. healthcare moves toward decentralized diagnostics, smaller-volume specimens, specialized testing, and integrated sample-to-result workflows.

USA Blood Collection Devices Market By End-User
• Hospitals and ambulatory surgery centers represent a highly diverse demand environment because blood collection occurs across emergency care, inpatient treatment, surgery, critical care, outpatient procedures, and routine diagnostics. The distinctive characteristic of this segment is the need for products that can function reliably across multiple clinical departments while supporting infection control, staff safety, rapid turnaround, and electronic workflow integration.
• Diagnostics and pathology laboratories place exceptional importance on pre-analytical specimen quality because errors introduced during collection can affect the reliability of subsequent testing. Consequently, tube/additive selection, specimen labeling, transport compatibility, hemolysis prevention, sample volume, and automation compatibility are major purchasing considerations. The U.S. laboratory environment also favors collection products capable of integrating into standardized and increasingly automated specimen-processing workflows.
• Blood banks and blood centers have a specialized demand profile centered on the collection and processing of blood intended for transfusion and related applications. Their requirements extend beyond basic specimen acquisition to include sterile collection, component separation, donor safety, traceability, compatibility with processing equipment, and protection of the blood supply.
• Other end users include physician offices, outpatient facilities, emergency departments, research organizations, home-care settings, and specialized healthcare environments. This segment is characterized by demand for simpler, portable, and application-specific collection solutions that can operate outside traditional centralized laboratory environments. The expansion of point-of-care and decentralized testing makes ease of use, sample-volume reduction, transportability, and integration with compact diagnostic platforms increasingly important.

USA Blood Collection Devices Market By Application
• Diagnostic blood collection represents the broadest range of collection requirements because samples are used for hematology, clinical chemistry, immunology, coagulation, molecular testing, infectious-disease testing, and other laboratory investigations. The defining market characteristic is the close relationship between collection-device design and the analytical requirements of the downstream test. Tube additives, specimen volume, anticoagulation, serum or plasma preparation, contamination control, and sample stability can all influence test performance.
• Therapeutic blood collection is differentiated from diagnostic sampling because the collected blood or blood component is itself part of a treatment pathway. The segment encompasses collection associated with transfusion medicine, blood-component preparation, therapeutic procedures, apheresis, and other blood-processing applications. As a result, device requirements emphasize sterility, controlled collection, component integrity, patient and donor safety, and compatibility with separation and processing systems.

USA Blood Collection Devices Market By Method
• Manual blood collection remains important because venipuncture and capillary sampling require clinical judgment, patient assessment, positioning, vein selection, and adaptation to individual circumstances. Its main differentiator is flexibility: healthcare professionals can modify the collection approach based on patient anatomy, age, vascular access, specimen requirements, and clinical conditions.
• Automated blood collection encompasses technologies designed to reduce operator dependence and introduce greater consistency into collection, monitoring, and blood-processing workflows. Its strongest relevance is in environments where collection is repetitive, high-throughput, technically complex, or closely linked to component separation and processing. Automation can also support standardized collection parameters, process monitoring, documentation, and integration with broader laboratory or blood-bank infrastructure.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Blood Collection Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Blood Collection Tubes
• Needles & Syringes
• Blood Bags
• Blood Collection Systems/Monitors
• Lancets
• Others

By End-User
• Hospitals and ASCs
• Diagnostics and Pathology Laboratories
• Blood Banks
• Others

By Application
• Diagnostic Application
• Therapeutic Application

By Method
• Manual
• Automated